Novo Nordisk's steep stock decline has pushed it into deep undervaluation, now trading at attractive multiples below ...

Once the golden child of the weight-loss boom, the Danish drugmaker now faces a painful financial slimming of its own.

Lilly's weight-loss medications Mounjaro and Zepbound are gaining market share on Novo's Wegovy and Ozempic, but investors ...

By Twesha Dikshit (Reuters) -European stocks edged higher on Friday, led by upbeat corporate earnings and a jump in Novo ...

Novo Nordisk remains the GLP-1 leader with over 65% market share. Read an in-depth BVO stock analysis and why we rate it as a ...

CNBC's Silvia Amaro takes a look at the rise and fall in Novo Nordisk shares. Kelly Clarkson's ex-husband Brandon Blackstock ...

Rather, it was the Danish pharmaceutical company's No. 1 rival. Appreciative investors bid up Novo Nordisk's stock in a ...

Shares rose for a second day, in a rally sparked by rival Eli Lilly (LLY) reporting less-than-stellar trial results for an ...

Novo Nordisk expects continued competition from copycat versions of its blockbuster Wegovy obesity drug this year and could ...

Novo Nordisk A/S (NYSE:NVO) on Wednesday reported second-quarter 2025 sales of roughly $11.68 billion (76.86 billion Danish ...

Novo Nordisk has abandoned another GLP-1/GIP co-agonist and CB1 receptor as part of a significant pipeline clearout that ...

The investment conglomerate reported a higher-than-expected profit, aided by a recovery in its te ...